Outcome-adaptive randomization: Is it useful?

Journal of Clinical Oncology

Volumn 29, Issue 6, 2011, Pages 771-776

  Korn, Edward L ^a   Freidlin, Boris ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; EXPERIMENTAL STUDY; EXPERIMENTAL THERAPY; HUMAN; OUTCOME ADAPTIVE RANDOMIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE;

HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 78650339993     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.1423     Document Type: Review

References (24)

1. Maki RG, Wathen JK, Patel SR, et al: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25:2755-2763, 2007 (Pubitemid 47123184)
2. Faderl S, Ravandi F, Huang X, et al: A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112:1638-1645, 2008
3. Adamina M, Tomlinson G, Guller U: Bayesian statistics in oncology: A guide for the clinical investigator. Cancer 115:5371-5381, 2009
4. Berry DA: Bayesian clinical trials. Nat Rev Drug Discov 5:27-36, 2006
5. Biswas S, Liu DD, Lee JJ, et al: Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials 6:205-216, 2009
6. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005
7. Brittain E, Schlesselman JJ: Optimal allocation for the comparison of proportions. Biometrics 38:1003-1009, 1982
8. Berry DA, Eick SG: Adaptive assignment versus balanced randomization in clinical trials: A decision analysis. Stat Med 14:231-246, 1995
9. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
10. Rosenberger WF, Stallard N, Ivanova A, et al: Optimal adaptive designs for binary response trials. Biometrics 57:909-913, 2001 (Pubitemid 32801189)
11. Bandyopadhyay U, Bhattacharya R: Adaptive allocation and failure saving in randomised clinical trials. J Biopharm Stat 16:817-829, 2006 (Pubitemid 44764447)
12. Thall PF, Wathen JK: Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 43:859-866, 2007 (Pubitemid 46366693)
13. Thompson WR: On the likelihood that one unknown probability exceeds another in view of the evidence of the two samples. Biometrika 25:285-294, 1933
14. Giles FJ, Kantarjian HM, Cortes JE, et al: Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21:1722-1727, 2003 (Pubitemid 46638583)
15. Freidlin B, Korn EL, Gray R: A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials 7:197-208, 2010
16. Cheung YK, Inoue LY, Wathen JK, et al: Continuous Bayesian adaptive randomization based on event times with covariates. Stat Med 25:55-70, 2006 (Pubitemid 43136949)
17. Cornfield J, Halperin M, Greenhouse SW: An adaptive procedure for sequential clinical trials. J Am Stat Assoc 64:759-770, 1969
18. Weinstein MC: Allocation of subjects in medical experiments. N Engl J Med 291:1278-1285, 1974
19. Byar DP, Simon RM, Friedewald WT, et al: Randomized clinical trials: Perspectives on some recent ideas. N Engl J Med 295:74-80, 1976
20. Wei LJ, Durham S: The randomized play-the-winner rule in medical trials. J Am Stat Assoc 73:840-843, 1978
21. Jennison C, Turnbull BW: Group Sequential Methods With Applications to Clinical Trials. New York, NY, Chapman & Hall, 2000
22. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
23. Freidlin B, Korn EL, Gray R, et al: Multi-arm clinical trials of new agents: Some design considerations. Clin Cancer Res 14:4368-4371, 2008
24. Freidlin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: Design issues. J Natl Cancer Inst 102:152-160, 2010